Electrome Announces Expanded Research Partnership Program

Electrome Corporation today announced an expanded research partnership program supporting academic and clinical investigators conducting bioelectric science research. The program builds on the existing collaboration with Tulane University on the LymeCure work and adds defined paths for mechanism, clinical observation, cross modal, and data only collaborations.

Program scope

The research office supports investigators with device access, defined protocol parameters, letters of support, and where appropriate, structured access to platform data under data sharing agreements. Investigators retain authorship and intellectual ownership of their work.

About the partnership

The research partnership announced today extends the Electrome research office's network of academic collaborators working on bioelectric mechanism, clinical translation, and adjacent questions. The partnership is structured around defined research questions, governed by data sharing agreements that protect patient privacy, and supported by the platform's longitudinal data infrastructure. The investigators retain authorship and intellectual ownership of the work, and the publications produced through the partnership go through the same peer review process that any rigorous research goes through.

Why partnerships of this kind matter

Bioelectric medicine is at a stage where the most useful research questions are increasingly multi disciplinary, combining mechanism work, clinical translation, and longitudinal data analysis. Academic partnerships are how those questions get worked on at the necessary depth. The Electrome platform's role is to provide the infrastructure that makes the research efficient. The investigators' role is to provide the methodological rigor that makes the research credible. The combination is part of how the bioelectric category continues to mature.

About Electrome Corporation

Electrome Corporation operates the bioelectric medicine platform behind PAINKILLER and supports a research portfolio that includes the LymeCure collaboration with Tulane and a growing network of academic partnerships. The company's stated posture is to support rigorous research, to keep research clearly separated from cleared clinical claims, and to make platform infrastructure available to investigators on terms that respect the rigor and the autonomy of the work.